SCOLR PHARMA, INC. (SCLR)

HEALTH CARE: PHARMACEUTICALS
SIC: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

19204 NORTH CREEK PARKWAY BOTHELL, WA 98011

SCOLR Pharma, Inc., a pharmaceutical company, develops and commercializes prescription, over-the-counter, and nutritional products. The company uses its controlled delivery technology platform and develops water soluble and insoluble drugs, as well as high and low dose drugs; analgesic, cardiovascular, diabetes, anti-nausea, and pulmonary products; and dietary supplement products, including combinations of glucosamine and chondroitin, calcium, and other dietary products. Its lead drug product candidates include a 12 hour extended release formulation of ibuprofen, an analgesic for the treatment of pain, fever, and inflammation, which has completed Phase III clinical trial; and 12 hour Pseudoephedrine, a decongestant that is used to relieve sinus pressure related to allergies and common cold. The company is also developing IR Raloxifene for osteoporosis; ER Ondansetron, an anti-nausea drug; ER Phenylephrine a decongestant; and ER Niacin for cardiovascular disorders. In addition, it provides various formulation products for applications, including expectorant analgesic, sleep aid, cough-cold, decongestant and antihistamine, hypercholesterolemia and hypertriglyceridemia, pain management, beta-blockers, Ca Channel blockers, Alzheimer's disease, schizophrenia/bi-polar, diabetes, motion sickness, asthma, and bronchodilator. SCOLR Pharma, Inc. has a strategic alliance with Perrigo Company of South Carolina, Inc. for the manufacture, marketing, distribution, and sale of certain dietary supplements in the United States; and research collaboration with BioCryst Pharmaceuticals to develop an oral formulation of peramivir for the treatment of seasonal and life threatening influenza.

View SEC Filings from SCLR instead.
Q1 2021 All 13F Filers Prior Change Hedge Funds 1 Prior Change
No data found for this quarter.
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding SCLR (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding SCLR BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

TURNER STEPHEN PRESIDENT & CEO

  • Officer
0 2012-02-02 0

LEVY RICHARD M CFO & EXEC. VP FINANCE

  • Officer
0 2012-02-02 0

TAGLICH MICHAEL N

  • Director
0 2011-06-16 0

LUCAS HERBERT L JR

  • Director
0 2011-06-09 0

PINES WAYNE L

  • Director
0 2011-06-09 0

JEFFREY REICH

  • Director
0 2011-06-09 0

JOHNSON CARL J

  • Director
0 2011-06-09 0

ARNETT MARYLOU W

  • Director
0 2011-06-09 0

MORRA BRUCE S

  • Director
214,285 2010-01-04 0

MITCHEL ALAN M SR. VP - CHIEF LEGAL OFFICER

  • Officer
0 2009-10-28 0

CAUDILL RANDALL L W

  • Director
0 2009-06-11 0

WILDS DANIEL O CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
109,000 2008-11-19 0

WEAVER GREGORY L

  • Director
0 2008-06-05 0

FASSIHI REZA

  • Director
0 2008-06-05 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments